MCID: FML039
MIFTS: 48

Female Reproductive System Disease malady

Categories: Reproductive diseases

Aliases & Classifications for Female Reproductive System Disease

Aliases & Descriptions for Female Reproductive System Disease:

Name: Female Reproductive System Disease 12 14
Female Reproductive System Disorder 69
Genital Diseases, Female 42

Classifications:



External Ids:

Disease Ontology 12 DOID:229
ICD9CM 35 629.9
MeSH 42 D005831
UMLS 69 C0017411

Summaries for Female Reproductive System Disease

Disease Ontology : 12 A reproductive system disease that impairs the ability to reproduce and is located in the uterus, vagina, cervix, ovaries or fallopian tubes.

MalaCards based summary : Female Reproductive System Disease, also known as female reproductive system disorder, is related to uterine disease and ectopic pregnancy, and has symptoms including leukorrhea, mastodynia and genital itching. An important gene associated with Female Reproductive System Disease is AMH (Anti-Mullerian Hormone), and among its related pathways/superpathways are TGF-Beta Pathway and PAK Pathway. The drugs Desogestrel and Etonogestrel have been mentioned in the context of this disorder. Affiliated tissues include cervix, ovary and uterus, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Related Diseases for Female Reproductive System Disease

Diseases related to Female Reproductive System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
id Related Disease Score Top Affiliating Genes
1 uterine disease 10.9
2 ectopic pregnancy 10.9
3 endometriosis 10.9
4 perinatal jaundice due to hepatocellular damage 10.4 AMH CYP19A1 PGR
5 deafness, autosomal recessive 74 10.4 CYP19A1 GNRH1 PGR
6 glioblastoma mesenchymal subtype 10.4 CYP19A1 PRL SHBG
7 vitreoretinopathy, neovascular inflammatory 10.3 CXCL8 IL6 SERPINH1
8 sex differentiation disease 10.3 CYP19A1 FOXL2 PGR
9 adult neuronal ceroid lipofuscinosis 10.3 PGR PRL VEGFA
10 retroperitoneal sarcoma 10.3 AMH GNRH1 PRL SHBG
11 haverhill fever 10.3 CYP19A1 GNRH1 PGR PRL
12 nephrogenic adenofibroma 10.3 CYP19A1 GNRH1 PGR
13 pelvic muscle wasting 10.3 CYP19A1 GNRH1 PRL SHBG
14 endocervicitis 10.3 FSHR PGR VEGFA
15 papillary craniopharyngioma 10.3 GNRH1 PRL VEGFA
16 aphasia 10.3 OXT PRL SHBG
17 glycerol kinase deficiency, adult form 10.3 CYP19A1 PGR VEGFA
18 oculomotor nerve paralysis 10.3 CXCL8 IL1B IL6
19 common peroneal nerve lesion 10.3 CXCL8 IL1B IL6
20 stevens-johnson syndrome/toxic epidermal necrolysis 10.3 IL1B SERPINH1 VEGFA
21 46 xx gonadal dysgenesis 10.3 AMH BMP15 FOXL2 FSHR
22 carbuncle 10.3 CXCL8 IL1B IL6
23 intramuscular hemangioma 10.3 AMH BMP15 GNRH1 OXT
24 capillary disease 10.3 CYP19A1 PGR PRL SHBG
25 acquired thrombocytopenia 10.3 CXCL8 IL1B IL6
26 immunodeficiency due to a late component of complement deficiency 10.3 CXCL8 PGR VEGFA
27 autosomal recessive type iv ehlers-danlos syndrome 10.3 CXCL8 IL1B IL6
28 bipolar i disorder 10.3 IL1B IL6 VEGFA
29 kidney benign neoplasm 10.3 FSHR PGR VEGFA
30 inappropriate adh syndrome 10.3 CXCL8 IL1B IL6
31 labyrinthitis 10.3 CXCL8 IL1B IL6
32 ectodermal dysplasia bartalos type 10.3 IL1B IL6 VEGFA
33 atrophy of prostate 10.3 CXCL8 IL1B IL6
34 chordoid meningioma 10.3 CXCL8 IL1B IL6
35 choroiditis 10.3 CXCL8 IL1B IL6
36 nasopharyngitis 10.3 CXCL8 IL1B IL6
37 glandular cystitis 10.3 IL1B IL6 OXT
38 sphingolipidosis 10.3 AMH CYP19A1 GNRH1 PRL SHBG
39 metagonimiasis 10.3 IL6 PGR VEGFA
40 gaucher's disease 10.3 AMH CYP19A1 GNRH1 PRL SHBG
41 breast apocrine carcinoma in situ 10.3 CXCL8 IL1B IL6
42 stenosis of lacrimal sac 10.3 CXCL8 IL1B IL6
43 capillary lymphangioma 10.3 AMH FSHR GNRH1 PRL SHBG
44 baritosis 10.3 CXCL8 IL1B IL6
45 childhood electroclinical syndrome 10.3 CXCL8 IL1B IL6 SERPINH1
46 bullous retinoschisis 10.3 CXCL8 IL1B IL6 SERPINH1
47 deep leiomyoma 10.3 FOXL2 NOBOX PRL VEGFA
48 neuropathy 10.3 CXCL8 IL1B IL6 SERPINH1
49 paragonimiasis 10.2 CXCL8 IL6 OXT
50 colon adenocarcinoma 10.2 CXCL8 IL1B IL6

Graphical network of the top 20 diseases related to Female Reproductive System Disease:



Diseases related to Female Reproductive System Disease

Symptoms & Phenotypes for Female Reproductive System Disease

UMLS symptoms related to Female Reproductive System Disease:


leukorrhea, mastodynia, genital itching, pruritus vulvae, vaginal pruritus, breast engorgement, nipple discharge, menometrorrhagia, perineal pain female, genitalia external painful, vaginal odor, menopausal symptoms, vaginal discomfort, vaginal pain, burning feeling vagina, mastoscirrhus, discomfort of vulva

MGI Mouse Phenotypes related to Female Reproductive System Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.27 AMH AREG BMP15 CYP19A1 FMR1 FOXL2
2 homeostasis/metabolism MP:0005376 10.13 AMH AREG CYP19A1 FOXL2 FSHR GDF9
3 integument MP:0010771 10 VEGFA AREG CYP19A1 FMR1 FSHR GNRH1
4 neoplasm MP:0002006 9.76 AMH FSHR GNRH1 IL1B IL6 PGR
5 nervous system MP:0003631 9.7 NOBOX OXT PRL SERPINH1 VEGFA CYP19A1
6 reproductive system MP:0005389 9.53 VEGFA ZP3 AMH AREG BMP15 CYP19A1

Drugs & Therapeutics for Female Reproductive System Disease

Drugs for Female Reproductive System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1156)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Desogestrel Approved Phase 4,Phase 3,Phase 2 54024-22-5 40973
2
Etonogestrel Approved, Investigational Phase 4,Phase 2,Phase 3 54048-10-1 40976 6917715
3
Levonorgestrel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 797-63-7, 17489-40-6 13109
4
Calcium carbonate Approved Phase 4,Phase 3 471-34-1
5
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
6
Tibolone Approved Phase 4 5630-53-5
7
Ganirelix Approved Phase 4,Phase 3,Phase 2,Early Phase 1 123246-29-7, 124904-93-4 25081094
8
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
9
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53714-56-0 3911 657181
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
11
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757 53477783
12
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
13
Cetrorelix Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 120287-85-6 16129715 25074887
14
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
15
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
16
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
17
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 18323-44-9 29029
18
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
19
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 616-91-1 12035
20
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 443-48-1 4173
21
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 71-58-9
22
Bupivacaine Approved, Investigational Phase 4,Phase 1 2180-92-9, 38396-39-3 2474
23
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
24
Norethindrone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68-22-4 6230
25
Selenium Approved, Vet_approved Phase 4,Phase 3,Phase 2 7782-49-2
26
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3 427-51-0
27
Drospirenone Approved Phase 4,Phase 3,Phase 1,Early Phase 1 67392-87-4 68873
28
Orlistat Approved, Investigational Phase 4,Phase 3,Phase 2 96829-58-2 3034010
29
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 55185 53477736 447043
30
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 564-25-0 54671203
31
Lymecycline Approved Phase 4 992-21-2 5280963
32
Tetracycline Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 60-54-8 5353990
33
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
34
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
35
Menotropins Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 61489-71-2 5360545
36
Buserelin Approved Phase 4,Phase 3 57982-77-1
37
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 137-58-6 3676
38
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
39
Nystatin Approved, Vet_approved Phase 4,Phase 3 1400-61-9 11953884
40
Mefenamic acid Approved Phase 4,Phase 2,Phase 3 61-68-7 4044
41
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 1197-18-8 5526
42
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 354812-41-2, 151096-09-2 152946
43
Norgestimate Approved Phase 4,Phase 3,Phase 2,Phase 1 35189-28-7 6540478
44
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3 9004-61-9 53477741 24759
45
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
46
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
47
Menthol Approved Phase 4,Phase 3,Phase 1,Early Phase 1 2216-51-5 16666
48
Misoprostol Approved Phase 4,Phase 3,Phase 2 59122-46-2 5282381
49
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
50
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681

Interventional clinical trials:

(show top 50) (show all 5960)
id Name Status NCT ID Phase
1 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4
2 National,Multicentric Randomised Study of the Correction of Genital Prolapse With Fascial Repair or Mesh-Prolift Unknown status NCT00771225 Phase 4
3 Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis Unknown status NCT02480647 Phase 4
4 Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis Unknown status NCT00654524 Phase 4
5 Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF Unknown status NCT02070198 Phase 4
6 IUI vs. IVF/ICSI in Women Aged 38-42 Years: a Prospective Randomized Controlled Trial. Unknown status NCT01992731 Phase 4
7 Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure Unknown status NCT02329197 Phase 4
8 The Effect of LH-Priming During Early Follicular Phase in IVF Treatment. Unknown status NCT00334425 Phase 4
9 Type of Gonadotropin and Embryo Kinetics of Development Unknown status NCT02402192 Phase 4
10 Physical Activity and ARTs Unknown status NCT01892111 Phase 4
11 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4
12 Ovarian Stimulation: Inositol and Melatonin Unknown status NCT01267604 Phase 4
13 Study of Dual Trigger Ovulation in Oocyte Donors Unknown status NCT01443546 Phase 4
14 Ovulation Induction With Clomiphene Citrate and Dexamethasone Unknown status NCT01856062 Phase 4
15 Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients Unknown status NCT01353846 Phase 4
16 Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation Unknown status NCT00417183 Phase 4
17 Corifollitropin Alfa Versus Follitropin Beta in High Responders Unknown status NCT02471677 Phase 4
18 Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders Unknown status NCT01926210 Phase 4
19 Intrauterine Insemination and Luteal Fase Support Unknown status NCT01826747 Phase 4
20 Luteal Phase Support With Progesterone Versus Estrogen and Progesterone on Pregnancy Rates Unknown status NCT01237535 Phase 4
21 Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs Unknown status NCT00415792 Phase 4
22 Botox on Vulvar Vestibulitis Unknown status NCT00119886 Phase 4
23 Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4
24 CavatermTM vs TCRE in Women With DUB Unknown status NCT00549159 Phase 4
25 Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy Unknown status NCT01558388 Phase 4
26 Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4
27 A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Unknown status NCT01074892 Phase 4
28 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4
29 Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy Unknown status NCT01779193 Phase 4
30 Functional Outcome After Groin Hernia Mesh Repair: Open Versus Laparoscopy Unknown status NCT00625534 Phase 4
31 Continuous Postoperative Use of Low-Dose Combined Oral Contraceptivesfor for Endometriosis-Related Chronic Pelvic Pain Unknown status NCT00844012 Phase 4
32 A New Treatment Option for Heavy Menstrual Bleeding Unknown status NCT01715025 Phase 4
33 Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain Unknown status NCT02022722 Phase 4
34 Treatment of Infertility by Collagen Scaffold Loaded With Autologous Bone Marrow Stem Cells Unknown status NCT02204358 Phase 4
35 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Unknown status NCT01815138 Phase 4
36 Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding Unknown status NCT01391052 Phase 4
37 Selenium Supplementation in Pregnancy Unknown status NCT01465867 Phase 4
38 Surgical Treatment To Greater Anterior Vaginal Prolapse Unknown status NCT00676325 Phase 4
39 Comparative Study of Mesh Versus No Mesh in Prolapse Surgery Unknown status NCT00153257 Phase 4
40 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
41 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
42 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4
43 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4
44 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4
45 Effects of ADSC Therapy in Women With POF Unknown status NCT01853501 Phase 4
46 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4
47 Continuous Versus Cyclic Oral Contraceptives for Endometriosis Unknown status NCT02237131 Phase 4
48 Multi-center Clinical Trials of Sanjie Analgesic Capsule in Treating Endometriosis Unknown status NCT02031523 Phase 4
49 The Hysteroscopic Morcellator (HM). Unknown status NCT01537822 Phase 4
50 Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced Unknown status NCT01661985 Phase 4

Search NIH Clinical Center for Female Reproductive System Disease

Cochrane evidence based reviews: genital diseases, female

Genetic Tests for Female Reproductive System Disease

Anatomical Context for Female Reproductive System Disease

MalaCards organs/tissues related to Female Reproductive System Disease:

39
Cervix, Ovary, Uterus, Breast

Publications for Female Reproductive System Disease

Variations for Female Reproductive System Disease

Expression for Female Reproductive System Disease

Search GEO for disease gene expression data for Female Reproductive System Disease.

Pathways for Female Reproductive System Disease

Pathways related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 AREG BMP15 CXCL8 GDF9 GNRH1 IL1B
2
Show member pathways
13.19 AREG BMP15 CXCL8 GDF9 GNRH1 IL1B
3
Show member pathways
12.59 AREG GDF9 GNRH1 IL1B IL6
4 12.04 CXCL8 IL1B IL6 VEGFA
5 11.78 CXCL8 IL1B IL6
6 11.76 CXCL8 IL1B IL6 VEGFA
7 11.72 CXCL8 IL1B IL6
8 11.69 CXCL8 IL6 PRL
9 11.65 CXCL8 IL1B IL6
10 11.62 CXCL8 IL1B IL6 VEGFA
11 11.54 CXCL8 IL1B IL6
12 11.51 CXCL8 IL1B IL6 VEGFA
13 11.46 CXCL8 IL1B IL6
14 11.42 CXCL8 IL6 VEGFA
15 11.38 CXCL8 IL1B IL6
16 11.36 CXCL8 IL1B IL6
17 11.31 CYP19A1 IL1B IL6
18
Show member pathways
11.26 CXCL8 IL1B IL6 VEGFA
19 11.11 AREG IL1B IL6
20 11.09 BMP15 CXCL8 IL1B IL6
21 10.98 AREG CYP19A1 FSHR
22 10.96 BMP15 CYP19A1 FSHR GDF9
23 10.73 FSHR GNRH1
24 10.53 CYP19A1 FSHR GDF9 PGR ZP3

GO Terms for Female Reproductive System Disease

Cellular components related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 AMH BMP15 CXCL8 GDF9 GNRH1 IL1B
2 extracellular space GO:0005615 9.4 AMH AREG BMP15 CXCL8 GDF9 GNRH1
3 secretory granule GO:0030141 9.35 IL1B OXT PRL VEGFA ZP3

Biological processes related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 AREG GDF9 IL6 PRL VEGFA
2 female pregnancy GO:0007565 9.8 GNRH1 OXT PRL
3 response to lipopolysaccharide GO:0032496 9.8 GNRH1 IL1B IL6 PRL
4 cell-cell signaling GO:0007267 9.8 AMH AREG GNRH1 IL1B PGR
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 AREG IL6 VEGFA
6 BMP signaling pathway GO:0030509 9.76 AMH BMP15 GDF9
7 response to glucocorticoid GO:0051384 9.73 AREG IL6 OXT
8 positive regulation of epithelial cell proliferation GO:0050679 9.72 IL6 PRL VEGFA
9 positive regulation of T cell proliferation GO:0042102 9.71 IL1B IL6 ZP3
10 response to peptide hormone GO:0043434 9.63 AREG GNRH1 OXT
11 induction of positive chemotaxis GO:0050930 9.62 CXCL8 VEGFA
12 positive regulation of leukocyte migration GO:0002687 9.61 VEGFA ZP3
13 regulation of MAPK cascade GO:0043408 9.61 BMP15 FSHR GDF9
14 gonad development GO:0008406 9.6 AMH FSHR
15 negative regulation of bone resorption GO:0045779 9.59 FSHR IL6
16 ovulation cycle GO:0042698 9.57 GNRH1 PRL
17 response to prostaglandin E GO:0034695 9.52 GNRH1 OXT
18 positive regulation of histone phosphorylation GO:0033129 9.51 FMR1 IL1B
19 female gonad development GO:0008585 9.5 CYP19A1 FOXL2 FSHR
20 positive regulation of prostaglandin secretion GO:0032308 9.48 IL1B OXT
21 female gamete generation GO:0007292 9.43 BMP15 FSHR GDF9
22 oocyte growth GO:0001555 9.37 FOXL2 GDF9
23 uterus development GO:0060065 9.33 CYP19A1 FOXL2 FSHR
24 ovarian follicle development GO:0001541 9.26 BMP15 FOXL2 NOBOX VEGFA
25 response to organic cyclic compound GO:0014070 9.1 AMH AREG GNRH1 IL6 OXT PRL

Molecular functions related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.46 AMH GNRH1 OXT PRL
2 transforming growth factor beta receptor binding GO:0005160 9.43 AMH BMP15 GDF9
3 growth factor activity GO:0008083 9.43 AMH AREG BMP15 GDF9 IL6 VEGFA
4 cytokine activity GO:0005125 9.17 AREG BMP15 CXCL8 GDF9 IL1B IL6

Sources for Female Reproductive System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....